Drug-induced pulmonary toxicity is a growing concern in modern oncology. While tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have revolutionized lung cancer treatment, they carry specific risks. Consequently, clinicians must identify these adverse events early to prevent severe outcomes. Pneumonitis remains the most significant pulmonary complication, often requiring rapid intervention and multidisciplinary care.

Incidence and Risk Factors

The incidence of pulmonary toxicity varies significantly between drug classes. For instance, EGFR-TKIs like gefitinib show a worldwide incidence of approximately 1%. However, some studies in specific populations report higher rates. Conversely, ICIs exhibit pneumonitis rates between 3% and 5% in monotherapy. This risk increases notably when doctors prescribe combination therapies. Key risk factors include male sex, smoking history, and pre-existing interstitial lung disease.

Management of Drug-induced Pulmonary Toxicity

Early recognition is paramount because these events can be life-threatening. Therefore, clinicians should maintain a high index of suspicion whenever a patient develops new respiratory symptoms. If you suspect pneumonitis, you must rule out infections and disease progression first. Standard management involves withholding the offending agent and initiating corticosteroids. For grade 2 symptoms, experts recommend oral prednisone at 1–2 mg/kg/day. However, grade 3 or 4 cases require hospitalization and intravenous methylprednisolone.

Expert opinion emphasizes that specialized centers should handle complex cases. Since immunotherapy effects can persist, monitoring must continue even after stopping the drug. Therefore, thorough baseline assessments and regular follow-ups are essential for patient safety.

Frequently Asked Questions

How is drug-induced pulmonary toxicity diagnosed?

Diagnosis is primarily a process of exclusion. Clinicians use high-resolution CT scans to identify ground-glass opacities or organizing pneumonia patterns. Additionally, you must exclude infections, pulmonary embolism, and cancer progression through clinical and laboratory evaluation.

Can patients resume cancer therapy after pneumonitis?

Rechallenge depends on the severity grade. Patients with grade 1 or 2 pneumonitis may resume therapy once symptoms resolve and steroids are tapered. However, grade 3 or 4 events usually necessitate permanent discontinuation of the offending drug.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Komninos D et al. When cancer treatment affects the lungs: a clinical overview on pulmonary toxicity induced by new cancer drugs. Expert Rev Respir Med. 2026 Feb 20. doi: 10.1080/17476348.2026.2631816. PMID: 41717783.

2. Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126.

3. He Y, et al. Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management. Transl Lung Cancer Res. 2019;8(Suppl 2):S136-S145.